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Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor composed
of HIF-1 and HIF-1 that is the central regulator of responses to hypoxia. The specific binding of HIF-1 to
the hypoxia-responsive element (HRE) induces the transcription of genes that respond to hypoxic conditions,
including vascular endothelial growth factor (VEGF). Here we report that expression of HIF-1 is increased
in diverse Epstein-Barr virus (EBV)-infected type II and III cell lines, which express EBV latent membrane
protein 1 (LMP1), the principal EBV oncoprotein, as well as other latency proteins, but not in the parental
EBV-negative cell lines. We show first that transfection of an LMP1 expression plasmid into Ad-AH cells, an
EBV-negative nasopharyngeal epithelial cell line, induces synthesis of HIF-1 protein without increasing its
stability or mRNA level. The mitogen-activated protein kinase (MAPK) kinase inhibitor PD98059 markedly
reduces induction of HIF-1 by LMP1. Catalase, an H2O2 scavenger, strongly suppresses LMP1-induced
production of H2O2, which results in a decrease in the expression of HIF-1 induced by LMP1. Inhibition of
the NF-B, c-jun N-terminal kinase, p38 MAPK, and phosphatidylinositol 3-kinase pathways did not affect
HIF-1 expression. Moreover, LMP1 induces HIF-1 DNA binding activity and upregulates HRE and VEGF
promoter transcriptional activity. Finally, LMP1 increases the appearance of VEGF protein in extracellular
fluids; induction of VEGF is suppressed by PD98059 or catalase. These results suggest that LMP1 increases
HIF-1 activity through induction of HIF-1 protein expression, which is controlled by p42/p44 MAPK activity
and H2O2. The ability of EBV, and specifically its major oncoprotein, LMP1, to induce HIF-1 along with other
invasiveness and angiogenic factors reported previously discloses additional oncogenic properties of this tumor
virus.
Epstein-Barr virus (EBV) is a human herpesvirus that is
associated with several types of malignancies, such as Burkitt’s
lymphoma, lymphoproliferative disorders, T-cell lymphomas,
Hodgkin’s disease, invasive breast cancer, and nasopharyngeal
carcinoma (NPC) (4, 43). In all of the tumors, EBV infection
is predominantly latent. In latent infection, the EBV genes
expressed are restricted to six EBV nuclear antigens (EBNA1,
-2, 3A, 3B, 3C, and -LP), three latent membrane proteins
(LMP1, 2A, and 2B), and two small nonpolyadenylated
RNAs (EBER1 and 2). On the basis of the pattern of ex-
pression of the genes that encode these proteins, latency is
classified into three types. In type I latency, exemplified by
Burkitt’s lymphoma, only EBNA1, EBERs, and sometimes
LMP2A are expressed. In type II latency, exemplified by
Hodgkin’s disease and NPC, EBNA1, EBERs, and the three
LMPs are expressed. In type III latency, exemplified by EBV
lymphoproliferative diseases, the full set of EBNAs and LMPs,
as well as EBERs, is expressed (43).
LMP1 is considered an oncogenic protein because it has
transforming properties in continuous rodent fibroblast cell
lines and it is essential for immortalization of B lymphocytes in
culture (61). LMP1 is an integral membrane protein consisting
of 386 amino acids. Six transmembrane-spanning domains con-
nect a short N-terminal cytoplasmic domain with a long C-
terminal cytoplasmic tail (14). The C-terminal region of LMP1
contains two functional domains: C-terminal activation region
1 (CTAR1) and CTAR2. CTAR1, the proximal domain, inter-
acts with tumor necrosis factor-associated factors and activates
NF-B (39). CTAR2, the distal domain, interacts with tumor
necrosis factor receptor-associated death domain protein and
also activates NF-B (19). In addition, LMP1 activates the
c-jun N-terminal kinase (JNK) cascade through CTAR2 and
also stimulates p38 mitogen-activated protein kinase (p38
MAPK) through both CTAR1 and CTAR2 (12, 29). LMP1
also activates the p42/p44 MAPK pathway in Rat-1 fibroblasts
(46).
We have shown that LMP1 induces the expression of an
array of cellular invasion and metastasis factors, including ma-
trix metalloproteinase 9 (MMP-9), which plays a critical role in
tumor invasion (66). In addition, LMP1 induces vascular en-
dothelial growth factor (VEGF) through induction of cycloox-
ygenase 2 (COX-2) (40). Furthermore, LMP1 induces and
causes release of fibroblast growth factor 2 (FGF-2) into ex-
tracellular fluid (60). Several of the tumors in which LMP1 is
expressed are invasive; NPC, for example, is highly invasive
and is characterized by new-vessel formation. These observa-
tions suggest that a tumor virus may alter tumor cell phenotype
such that invasiveness and angiogenesis are promoted. With
EBV, LMP1 plays the central role in this complex process.
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Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic
helix-loop-helix transcription factor composed of HIF-1 and
HIF-1 subunits (62). HIF-1 is induced exponentially in re-
sponse to a decrease in the cellular O2 concentration, but
HIF-1 is not regulated by cellular oxygen tension (23). The
specific binding of HIF-1 to the hypoxic response element
(HRE) activates the transcription of genes whose products are
required for tumor progression, including VEGF, glucose
transporters, and insulin-like growth factor 2 (48). HIF-1
protein undergoes rapid ubiquitination and degradation by
proteasomes under normoxic conditions. The oxygen-depen-
dent turnover of HIF-1 protein is regulated by prolyl 4-hy-
droxylases that modify HIF-1 at two conserved proline resi-
dues (Pro-402 and Pro-564) located in the oxygen-dependent
degradation domain of the protein (5, 51). Under normal ox-
ygen conditions, HIF-1 is modified by prolyl hydroxylation,
which permits binding of von Hippel-Lindau protein (pVHL),
a recognition component of the E3 ligase complex. This bind-
ing promotes the ubiquitination and degradation of HIF-1.
Because proline hydroxylases require molecular oxygen and
iron for their enzymatic activity, exposure to hypoxia or treat-
ment with iron chelators results in HIF-1 stabilization (20,
67). HIF-1 target genes encode proteins that increase O2 de-
livery and mediate adaptive responses to O2 deprivation. Thus,
a single protein, HIF-1, appears to determine the responses
to hypoxic conditions of at least 40 genes (50, 52). HIF-1
activity is increased not only by intratumoral hypoxia but also
by genetic alterations, including PTEN and pVHL, as well as
gain-of-function mutations in oncogenes that activate the
phosphatidylinositol 3-kinase (PI3K), SRC, and MAPK signal
transduction pathways under normoxic conditions (22, 35, 45,
70, 71).
So far, only general stimuli have been identified that affect
HIF-1 function. In this report, we show that a specific onco-
genic viral protein, LMP1, induces synthesis of HIF-1 and
induces HIF-1 activity as a transcriptional factor. VEGF is
induced, at least in part, through this pathway.
MATERIALS AND METHODS
Cell cultures. KR-4 is an EBV-positive type III lymphoblastoid cell line (LCL).
The KH-1 and KH-2 lines are EBV-positive type II cell lines derived by fusion
of KR-4 and HeLa cells (human cervical carcinoma) (kind gifts of Maria Ma-
succi, Karolinska Institute, Stockholm, Sweden) (69). Ad-AH cells, kindly pro-
vided by Erik K. Flemington (Tulane University, New Orleans, La.), are an
EBV-negative human nasopharyngeal cell line (58). Human embryonic kidney
293 cells and HeLa cells were obtained from the American Type Culture Col-
lection.
MDA-MB-231 (human breast cancer cell line) and EBV-infected MDA-MB-
231 clones (C4A3, C1D12, C2G6, and C3B4) were generous gifts from Irene
Joab (INSERM EPI 03-34, IUH, Hospital Saint-Louis, Paris, France). The
MDA-MB-231 cells were infected with a recombinant virus provided by Kenzo
Takada (18, 53). The parental MDA-MB-231 cells and the C4A3 clone are
LMP1 negative. C1D12, C3G6, and C3B4 are LMP1-positive clones. LMP1
expression is strongest in the C3B4 clone and weakest in C4A3. KR-4 cells were
maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS),
penicillin, and streptomycin. MDA-MB-231 cells were maintained in RPMI 1640
medium with 10% FBS, 4 M L-glutamine, penicillin, and streptomycin. EBV-
infected MDA-MB-231 clones were maintained in the same medium but with
G418 at 700 g/ml. The other cells were maintained in Dulbecco modified Eagle
medium (DMEM) with 10% FBS, penicillin, and streptomycin.
Plasmids. pcDNA3-based LMP1 has been previously described (66). The
FLAG-tagged IB (S32A/S36A) expression plasmid (srIB) was kindly pro-
vided by Albert Baldwin (University of North Carolina). IB (S32A/S36A) is
not phosphorylated because of the S32 and S36 substitutions, which result in
prevention of both degradation of IB and subsequent translocation of NF-B
into the nucleus. The FLAG-tagged JNK1 dominant negative (DN) expression
plasmid is a generous gift from Roger J. Davis (11). The PGL3-based pGL-HRE
and pGL-HRE mut luciferase reporter plasmids, which contain wild-type HRE
oligonucleotide or HRE oligonucleotide with a CGT-to-AAA mutation, were
kind gifts from J. Silvio Gutkind (National Institutes of Health, Bethesda, Md.)
(see Fig. 5B) (54). The human VEGF gene luciferase reporter constructs
(1176/54 and 27/54), which were cloned in the pGL2 basic vector, were
kindly provided by Jacques Pouyssegur and Gilles Pages (University of Nice,
Nice, France) (36).
Transient and stable transfection. Cells were transfected with 2 g of the
appropriate plasmid(s) with the use of the Effectene transfection kit (QIAGEN)
in accordance with the manufacturer’s instructions. For luciferase reporter assay,
cells were transfected with 1 g of the appropriate plasmids by use of the
Superfect transfection kit (QIAGEN) in accordance with the manufacturer’s
protocol. Stable cell lines were established by cultivating Ad-AH cells in the
presence of 800 g of G418 per ml (Life Technologies).
Western blot analysis. Whole-cell lysates were extracted in 500 l of radio-
immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1% NP-40, 0.50% sodium deoxycholate, 0.10% sodium dodecyl sulfate
[SDS], 0.2 mM sodium orthovanadate, 0.1 M NaF, 5 g of fluoride per ml).
Nuclear or cytoplasmic extracts were prepared by the use of NE-Per (Pierce) in
accordance with the manufacturer’s protocol. Protein concentration was deter-
mined by Bio-Rad protein assay. Protein (50 to 100 g) was boiled in SDS
sample buffer for 5 min, electrophoresed on 6 to 10% polyacrylamide gels, and
transferred onto a nitrocellulose membrane (Osmonics). Nonspecific reactivity
was blocked by incubation for 30 min in a Tris-buffered saline solution containing
0.1% Tween 20 and 10% nonfat dried milk. The membrane was incubated
overnight at 4°C with (i) mouse LMP1 monoclonal antibody (DAKO), (ii) mouse
HIF-1 monoclonal antibody (Transduction Laboratories), (iii) mouse histone 1
monoclonal antibody (Santa Cruz), (iv) mouse GRP78 monoclonal antibody
(Santa Cruz), (v) mouse HIF-1 monoclonal antibody (Transduction Laborato-
ries), (vi) mouse FLAG M2 monoclonal antibody (Sigma), (vii) rabbit phospho-
p42/p44 MAPK polyclonal antibody (New England Biolabs), (viii) rabbit phos-
pho-p38 MAPK polyclonal antibody (New England Biolabs), or (ix) rabbit
phospho-Akt polyclonal antibody (New England Biolabs). The membrane was
washed with Tris-buffered saline solution containing 0.1% Tween 20, incubated
with a horseradish peroxidase-conjugated mouse or rabbit secondary antibody
(Amersham) at room temperature for 1 h, and washed three times for 15 min
with Tris-buffered saline–0.1% Tween 20. Peroxidase activity was detected by
enhanced chemiluminescence (Amersham).
RPA. The human HIF-1 expression vector pCEP4/HIF-13.2T7 was a gen-
erous gift from Gregg L. Semenza (57). PCR was performed with Hotstar Taq
DNA polymerase (QIAGEN) as follows: 35 cycles of 95°C for 30 s, 59°C for 30 s,
and 72°C for 30 s. The antisense primer was 5-CGCGGATCCCAGCCGCTG
GAGACACAATC-3, and the sense primer was 5-CCGGAATTCCAGCACT
ACTTCGAAGTGGC-3. The PCR product was doubly digested with BamHI
and EcoRI and subcloned into vector pcDNA3. When linearized with KpnI and
transcribed with SP6 RNA polymerase, the [-32P]UTP-labeled riboprobe pro-
tects 197 nucleotides of HIF-1 mRNA. A plasmid to generate a glyceraldehyde-
3-phosphate dehydrogenase riboprobe was supplied by United States Biochemi-
cals, Inc. The RNase protection assay (RPA) for detection of HIF-1 mRNA was
performed with total RNA and RNase protection kit II (Ambion) in accordance
with the manufacturer’s instructions and was described previously (60). Signal
intensities were calculated with a Molecular Dynamics Phosphorimager (Sunny-
vale) and ImageQuant software.
Determination of the half-life of HIF-1. Ad-AH cells were transfected with or
without pcLMP1 as described above. To determine the half-life of HIF-1
protein, cells were treated with 100 M cycloheximide to block protein synthesis.
Cells were harvested after being incubated with cycloheximide for 0 to 4 min.
Expression of HIF-1 was detected at each time point by Western blot analysis.
Metabolic labeling experiments. Ad-AH cells (10  105) were plated in a
100-mm-diameter dish, and 24 h later the cells were transfected with 2 g of
plasmids; 48 h later, the cells were serum starved for 20 h. The cells were washed
with phosphate-buffered saline PBS and pulse-labeled for 30 min with 0.3 mCi of
[35S]Met-Cys per ml in Met- and Cys-free DMEM. Whole-cell extracts were
prepared with RIPA buffer. Extract (500 g) was precleared with 30 l of protein
A/G beads (Santa Cruz) for 1 h. Ten microliters of HIF-1 antibody and 30 l
of protein A/G beads were added to the supernatant fluid, rotated overnight at
4°C, pelleted, and washed six times with 1 ml of RIPA buffer. An equal volume
of 2 SDS loading buffer was added, and the samples were boiled and fraction-
ated by SDS-polyacrylamide gel electrophoresis. The gel was dried, and signal
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intensities were calculated with a Molecular Dynamics Phosphorimager (Sunny-
vale) and ImageQuant software.
Proteasome inhibition assay. To determine whether LMP1-induced HIF-1
was caused by lowered degradation, we incubated Ad-AH cells with or without
LMP1 with 10 M MG132 (benzyloxycarbonyl-leu-leucinyl-leucinal; Calbio-
chem), a potent proteasome inhibitor. HIF-1 protein levels were detected by
Western blot analysis at different time points.
Luciferase reporter assay. Reporter assays were performed after transient
transfection of each construct as a reporter plasmid with Superfect (QIAGEN)
by following the manufacturer’s protocol. Luminescence was measured by a
luminometer, and the results are expressed as light units per microgram of total
protein. Relative luciferase activity was determined as follows. (i) Relative HRE
activity was HRE luciferase activity divided by HRE mut activity. (ii) Relative
VEGF activity was 1176/54 luciferase activity divided by 27/54 activity.
Determination of intracellular ROS generation. The reactive oxygen species
(ROS) measurement was performed in cell suspension by flow cytometry (6).
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) is a lipid-permeable,
nonfluorescent compound and is oxidized by intracellular ROS to form the
lipid-impermeable and fluorescent compound dichlorodihydrofluorescein (6,
64). The cells were preincubated in DMEM containing 10% FBS with or without
catalase. Cells were trypsinized and then resuspended in 1 ml of DMEM without
FBS to a final concentration of 106/ml. DCFH-DA (10 M) was added in cell
suspension, followed by incubation at 37°C for 30 min. The cells were then
centrifuged and resuspended in PBS for immediate determination of ROS gen-
eration by flow cytometry (FACScan; Becton-Dickinson) using 488 nm for exci-
tation and 525 nm for emission.
Electrophoretic mobility shift assay. Nuclear extracts were prepared from
Ad-AH cells as described previously (42). Cells were collected and centrifuged at
4,500  g for 2 min. The supernatant fluid was discarded, and the cells were
resuspended in 500 l of cell lysis buffer A (10 mM HEPES [pH 8.0], 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol [DTT], 200 mM sucrose, 0.5 mM
phenylmethylsulfonyl fluoride, 1 g of leupeptin per ml, 0.5% NP-40) for 5 min
at 4°C. The crude nuclei released by lysis were collected by microcentrifugation.
Nuclei were rinsed once in buffer A and resuspended in 100 l of buffer B (20
mM HEPES [pH 7.9], 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 1.0 mM DTT, 1 g of leupeptin per ml). Nuclei
were incubated on a rocking platform at 4°C for 30 min and clarified by centrif-
ugation for 5 min. A 21-bp double-stranded 32P-labeled oligonucleotide probe
containing HIF-1 binding site-spanning nucleotides 979 to 959 of the VEGF
5-flanking sequence (WT VEGF) was synthesized (57). We also prepared un-
labeled WT VEGF and MT VEGF, an oligonucleotide containing a 3-bp sub-
stitution in the HIF-1 binding site of WT VEGF. For the electrophoretic mobility
shift assay, 15 g of nuclear extract was incubated in DNA-binding buffer (10
mM Tris [pH 7.8], 50 mM NaCl, 1 mM EDTA, 5% glycerol, 1 l of 100 mM DTT
per ml) and poly(dI-dC) (75 ng total) for 20 min at room temperature. The
aliquots were then incubated with the WT VEGF probe in the presence or
absence of an excess amount of unlabeled oligonucleotide WT VEGF or MT
VEGF for 20 min at room temperature. Samples were loaded onto a 5% native
polyacrylamide gel in Tris-borate-EDTA buffer. The gel was vacuum dried and
exposed for autoradiography.
Determination of VEGF protein levels in cell culture medium. Subconfluent
cells were grown in six-well plates in 2.5 ml of DMEM containing 10% FBS with
or without drugs for 2 h. The cells were then incubated in DMEM containing
10% FBS without drugs for 6 h. The medium was collected and clarified by
centrifugation at 400  g for 5 min. The amount of VEGF in the supernatant
fluid was determined with an ELISA kit (VEGF-ELISA; R&D Systems) in
accordance with the manufacturer’s instructions. VEGF was expressed as pico-
grams of VEGF protein per milliliter of medium and per 105 cells.
Injection of cells into athymic mice. Ad-AH/pcDNA3 or Ad-AH/pcLMP1 (2
 106) cells, stably transfected with pcDNA3 or pcLMP1, in 0.1 ml of PBS were
inoculated subcutaneously into athymic nude mice. About 4 weeks after injec-
tion, the mice were sacrificed and equal amounts of each tumor were homoge-
nized in SDS sample buffer for Western blot analysis.
RESULTS
The level of HIF-1 protein is increased in latently infected
type II and III cells. KR-4 is a typical type III LCL. The KH-1
and KH-2 lines were derived by fusion of KR-4 and HeLa cells
(69). The level of HIF-1 protein is significantly higher in
KR-4, KH-1, and KH-2 cells, which express LMP1, than in
HeLa cells. The level of HIF-1 protein appeared to corre-
spond to the level of LMP1 in the different cell lines (Fig. 1A).
MDA-MB-231 is an EBV-negative breast cancer cell line.
C4A3, C1D12, C2G6, and C3B4 are EBV-infected clones de-
rived from the MDA-MB-231 parental cell line. C1D12, C2G6,
and C3B4 cells express LMP1. As shown in Fig. 1B, the
HIF-1 protein level is exaggerated in LMP1-positive clones.
These results prompted us to examine the role of LMP1 on the
induction of HIF-1 protein.
LMP1 induces expression of HIF-1 protein. Ad-AH is an
EBV-negative nasopharyngeal epithelial cell line. Stable or
transient transfectants of Ad-AH cells expressing LMP1 and
control Ad-AH cells were incubated under normoxic condi-
tions. In the whole-cell lysates, the expression of HIF-1 pro-
tein, but not HIF-1 protein, was significantly higher in LMP1-
expressing cells (Fig. 1C and D). Similarly, induction of
HIF-1 by LMP1 was detected in human embryonic kidney
293 cells (data not shown).
Since both Ad-AH/pcDNA3 and Ad-AH/pcLMP1 cells are
tumorigenic in athymic nude mice, we were able to determine
levels of HIF-1 in LMP1-expressing tumors growing in mice.
Western blotting showed that there was enhanced expression
of HIF-1 in tumors derived from Ad-AH/pcLMP1 cells com-
pared with Ad-AH/pcDNA3-derived tumors (Fig. 1E). These
results indicate that LMP1 induces HIF-1 expression in epi-
thelial cells both in vitro and in vivo. In addition to the increase
in HIF-1, HIF-1 needs to be accumulated in the nucleus to
act as a transcriptional factor. To determine the localization of
HIF-1, both the nuclear and cytoplasmic fractions were ana-
lyzed. As shown in Fig. 1F, HIF-1 protein was restricted to
the nucleus, and its level was significantly higher in LMP1-
expressing cells than in control cells. This result suggests that
induction by LMP1 of HIF-1 may contribute to its activation.
LMP1 does not affect the mRNA level or stability of HIF-1
but stimulates HIF-1 protein synthesis. To test whether
LMP1 can induce the expression of HIF-1 mRNA, Ad-AH
cells were transiently transfected with an LMP1 expression
plasmid. The level of HIF-1 mRNA detected by RPA was
increased by neither LMP1 nor 12,13-phorbol myristate ace-
tate (PMA) compared with that of Ad-AH cells transfected
with control vector pcDNA3 (Fig. 2A). Hypoxia increases the
level of HIF-1 through an increase in protein stability as a
result of decreased ubiquitin-dependent proteasomal degrada-
tion (56). In cells exposed to hypoxic conditions, the HIF-1
level remains constant over 60 min despite the lack of ongoing
synthesis of the protein in cells exposed to cycloheximide (32).
Under normoxic conditions, the half-life of HIF-1 is less than
5 min (30). To investigate whether a similar mechanism is
activated by LMP1, the kinetics of HIF-1 decay in Ad-AH
cells treated with cycloheximide were determined (Fig. 2B).
Regardless of whether cells were transfected with pcDNA3 or
pcLMP1, the half-life of HIF-1 protein remained essentially
the same at 4 min. These results indicate that LMP1 neither
stimulates HIF-1 mRNA expression nor inhibits HIF-1 pro-
tein degradation.
To analyze the rate of HIF-1 protein synthesis, serum-
starved Ad-AH cells were pulse-labeled with [35S]Met-Cys for
30 min, followed by immunoprecipitation of HIF-1. In con-
trast to the HIF-1 level in pcDNA3-transfected Ad-AH cells,
the 35S-labeled HIF-1 level in the LMP1-expressing cells was
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FIG. 1. (A) Levels of HIF-1 protein are increased in type II and III latently EBV-infected cells. KR-4, type III, is an LCL. The KH-1 and
KH-2, type II, cell lines are derived by fusion of KR-4 and HeLa cells (69). Levels of HIF-1 correspond to the level of LMP1 protein.
(B) MDA-MB-231 is an EBV-negative breast cancer cell line. C4A3, C1D12, C2G6, and C3B4 are EBV-infected clones derived from the
MDA-MB-231 parental cell line. C1D12, C2G6, and C3B4 express LMP1. HIF-1 protein levels are increased depending on LMP1 expression.
(C, D, E, and F) LMP1 induces expression of HIF-1 protein in Ad-AH cells, an EBV-negative nasopharyngeal epithelial cell line. Stable (C) or transient
(D and F) transfectants of Ad-AH cells, expressing or not expressing LMP1, were incubated under normoxic conditions. (E) HIF-1 levels are increased
in LMP1-expressing tumors grown in athymic nude mice. In the whole-cell lysates, the expression of HIF-1 was significantly greater in LMP1-expressing
Ad-AH cells detected by Western blotting (C, D, and E). The HIF-1 protein level was not affected by LMP1 (C and D). HIF-1 protein was restricted
to the nucleus, and its level was significantly higher in LMP1-expressing cells (F). Histone 1 and GRP78 are nuclear and cytoplasmic markers, respectively.
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FIG. 2. LMP1 does not affect the mRNA level or stability of HIF-1 but stimulates HIF-1 protein synthesis. (A) HIF-1 mRNA was detected
by RPA. HIF-1 mRNA was induced by neither LMP1 nor PMA. (B) Ad-AH cells were treated with cycloheximide to block protein synthesis.
The half-life of HIF-1 protein was constant at 4 min in both LMP1-expressing and control cells. (C) To analyze the rate of HIF-1 protein
synthesis, serum-starved Ad-AH cells were pulse-labeled with [35S]Met-Cys for 30 min, followed by immunoprecipitation of HIF-1 protein.
35S-labeled HIF-1 protein was increased in LMP1-expressing cells compared with that in pcDNA3-transfected Ad-AH cells by more than
threefold. For the positive control, pcDNA3-transfected Ad-AH cells were treated with PMA and pulse-labeled, followed by immunoprecipitation
of HIF-1 protein. For the negative control, LMP1-expressing Ad-AH cells were pulse-labeled, followed by immunoprecipitation by normal mouse
immunoglobulin G. N.C., negative control. (D) To determine whether the high level of HIF-1 protein detected in LMP1-positive cells was caused
by reduced proteasomal degradation, cells were incubated with MG132 and Western blot assays were performed at the indicated time points. At
all time points, levels of HIF-1 protein were significantly higher in LMP1-positive cells than in LMP1-negative cells regardless of the presence
of MG132. Data shown are representative of those obtained in three separate experiments.
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increased more than threefold (Fig. 2C). For controls, serum-
starved Ad-AH cells were pretreated with PMA, pulse-labeled,
and then immunoprecipitated by HIF-1 antibody for the pos-
itive control or by normal mouse immunoglobulin G for the
negative control. PMA is known to induce synthesis of HIF-1
protein without increasing its stability (44).
To determine whether decreased proteasomal degradation
produced the high level of HIF-1 protein detected in LMP1-
positive cells, we incubated cells with MG132, a potent pro-
teasome inhibitor, and then performed Western blot analysis
at different time points. At all of the time points, levels of
HIF-1 protein were significantly higher in LMP1-positive
cells than in LMP1-negative cells regardless of the presence of
MG132 (Fig. 2D). Therefore, the difference in HIF-1 protein
levels between LMP1-positive and LMP1-negative cells is at-
tributable not to differential degradation but to differential
expression. Thus, LMP1 increases the level of HIF-1 protein
not by induction of its transcription or its stabilization but by
increased synthesis of the protein.
The p42/p44 MAPK pathway is involved in LMP1-induced
HIF-1 expression. p42/p44 MAPK consists of two serine/
threonine protein kinases that modulate the activity of a
number of activation factors (10). Richard et al. showed that
activation of the p42/p44 MAPK pathway induced the phos-
phorylation of HIF-1, which was abolished in the presence of
the MAP/ERK (MEK) inhibitor PD98059. They also demon-
strated that p42/p44 MAPK activation is sufficient to promote
the transcriptional capacity of HIF-1 (45). Hur et al. have also
shown that PD98059 changes neither the stabilization nor the
DNA-binding ability of HIF-1, but it inhibits the ability of
HIF-1 to transactivate responsive promoters (17a). These
data suggest that the p42/p44 MAPK pathway is involved in
HIF-1 activity but not in HIF-1 induction. In contrast, Agani
and Semenza showed that mersalyl, a thioreactive organomer-
curial compound, induced the expression of HIF-1 and that
PD98059 markedly reduced induction of HIF-1 by mersalyl,
but not by hypoxia (1). The role of the p42/p44 MAPK signal-
ing pathway that influences HIF-1 overexpression and HIF-1
transcriptional activity remains somewhat confusing and
controversial. 	
 test whether the p42/p44 MAPK pathway is
involved in LMP1-induced HIF-1 expression, we treated
LMP1-transfected Ad-AH cells with PD98059. The expression
of LMP1-induced HIF-1 protein detected by Western blot-
ting was suppressed by PD98059 in a dose-dependent manner.
However, the effect of PD98059 on inhibition of HIF-1 phos-
phorylation was not clear (Fig. 3A). Although SB203580, a
selective p38 MAPK pathway inhibitor, suppressed the LMP1-
induced p38 MAPK activity to the basal level (12, 29), the drug
did not affect the expression of HIF-1 in our system (Fig. 3A).
Thus, p42/p44 MAPK signaling is involved in LMP1-induced
HIF-1 expression but the p38 MAPK pathway is not.
LMP1-induced H2O2 stimulates the expression of HIF-1
protein. ROS have been proposed to participate in the signal
transduction process mediating the stabilization and transla-
tion of HIF-1 (8, 44). We tested the effect of LMP1 on ROS
generation by measuring the fluorescence response by flow
cytometry and DCFH-DA and found that LMP1 increased
ROS production. Catalase, a hydrogen peroxide (H2O2) scav-
enger, decreased the generation of ROS to the basal level (Fig.
3B). These results suggest that ROS generated by LMP1 is
mostly H2O2. Next, we decided to investigate whether an in-
crease in H2O2 levels was responsible for the induction of
HIF-1 mediated by LMP1. When the cells were treated with
catalase, HIF-1 induction by LMP1 was completely blocked
(Fig. 3C). These results strongly suggest that HIF-1 induction
by LMP1 is mediated through H2O2 production.
The PI3K signaling pathway is not involved in LMP1-in-
duced HIF-1 expression. Previous reports suggest that PI3K
and Akt are central in the regulation of HIF-1 activity (24, 44,
71). First, we checked whether LMP1 induces PI3K activity by
detection of phospho-Akt by Western blotting. Akt is activated
by PI3K and lies between PI3K and FKBP-rapamycin-associ-
ated protein in this signaling pathway (28). As shown in Fig.
4A, LMP1 does not increase the amount of phospho-Akt,
which suggests that LMP1 does not stimulate the PI3K signal-
ing pathway. Next, to determine whether PI3K pathway activity
is required for LMP1-induced expression of HIF-1, cells were
exposed to wortmannin, an inhibitor of PI3K. Although wort-
mannin modestly suppressed phospho-Akt expression in a
dose-dependent manner, wortmannin did not affect the level of
HIF-1. Therefore, we conclude that PI3K signaling is not
involved in LMP1-induced HIF-1 expression.
NF-B and JNK signaling are not involved in LMP1-in-
duced HIF-1 expression. Recently, several reports have indi-
cated a role for NF-B signaling in HIF-1 induction (15, 26).
Jung et al. showed that microtubule-depolymerizing agents
induce HIF-1 at the transcriptional level, which depends on
activation of NF-B, in the A549 human lung cancer cell line
(26). Figueroa et al. showed that NF-B plays a key role in
HIF-1 protein expression and HIF-1 activation (15). We
checked the effect of NF-B signaling on HIF-1 expression by
cotransfecting LMP1 expression plasmid and srIB. Despite
the importance of NF-B in LMP1 signaling pathways, its
suppression by srIB did not affect the LMP1-induced
HIF-1 expression (Fig. 4B). Suppression of JNK signaling
also did not affect the expression of HIF-1 protein (Fig. 4B).
LMP1-induced HIF-1 has binding activity on the VEGF
promoter. Since LMP1 induces HIF-1 protein expression lo-
calized in the nucleus (Fig. 1E), we next checked whether
LMP1-induced HIF-1 could bind to the HRE of the VEGF
promoter. When a 21-bp oligonucleotide probe containing the
HIF-1-binding site from the VEGF promoter, WT VEGF (57),
was incubated with nuclear extract from Ad-AH cells with or
without LMP1 expression, complexes containing HIF-1 and a
constitutively expressed factor(s) were detected in LMP1-ex-
pressing cells (Fig. 5A, lane 3). An excess of unlabeled oligo-
nucleotide WT VEGF competed with the probe for binding of
HIF-1 (Fig. 5A, lane 5), whereas an oligonucleotide containing
a 3-bp substitution in the HIF-1 binding site (MT VEGF) did
not compete for binding (Fig. 5A, lane 7). These results indi-
cate that LMP1-induced HIF-1 is active and can bind to the
VEGF promoter.
LMP1-induced HIF-1 enhances HRE and VEGF luciferase
reporter activity. As shown in Fig. 5C and D, LMP1 upregu-
lates both HRE and VEGF luciferase reporter activities more
than twofold. Low-grade upregulation is a common feature of
VEGF luciferase reporter constructs (37). Having shown that
the p42/p44 MAPK pathway and H2O2 activity are involved in
LMP1-induced HIF-1 expression (Fig. 3A and C), we next
treated cells with PD98059, an MEK inhibitor, or catalase, an
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H2O2 scavenger, to determine the role of these pathways in
induction of VEGF by LMP1. PD98059 suppressed LMP1-
induced HRE reporter activity by 70% and completely abol-
ished VEGF reporter activity. In addition, catalase suppressed
both the HRE and VEGF reporter activities almost to the
basal level. These results indicate that LMP1-induced HIF-1
contributes to the transcriptional activation of the gene for
VEGF through HIF-1 activation, which depends on p42/p44
MAPK and H2O2 activities. We also checked the secretion of
VEGF in the culture medium. As noted before (40), LMP1
increased the level of VEGF protein in extracellular fluid (Fig.
5E). Furthermore, LMP1-induced VEGF was also suppressed
both by PD98059 and catalase.
DISCUSSION
In addition to the classical hypoxia-cobalt-desferrioxamine-
mediated induction of HIF-1, a number of agonists such as
insulin, insulin-like growth factor 1, angiotensin II, and the
organomercurial compound mersalyl also induce the expres-
sion of this transcription factor (1, 13, 16, 27, 59). These studies
suggest that while hypoxia remains the undisputed ubiquitous
inducer of HIF-1, other factors can also modulate increases in
HIF-1 protein levels under normoxic conditions. The signif-
icant findings from the present work can be briefly summarized
as follows: (i) LMP1, the principal EBV oncoprotein, induces
HIF-1 protein by increasing its synthesis without increasing
FIG. 3. The p42/p44 MAPK pathway and H2O2 are involved in
LMP1-induced HIF-1 expression. (A) Western blotting analysis to
determine the involvement of the p42/p44 MAPK pathway in LMP1-
induced expression of HIF-1 protein. LMP1-induced HIF-1 expres-
sion was suppressed in a dose-dependent manner by PD98059 but not
by SB203580. (B) LMP1 induces ROS activity, determined by measur-
ing the fluorescence response by flow cytometry and DCFH-DA. Cata-
lase, an H2O2 scavenger, completely suppresses LMP1-induced ROS
activity. Relative ROS activity represents the mean and standard de-
viation of three separate experiments. (C) HIF-1 expression was
analyzed by Western blotting to check the effect of catalase. Catalase
completely suppresses LMP1-induced HIF-1 expression. DMSO, di-
methyl sulfoxide.
VOL. 24, 2004 EBV AND HIF-1 5229
its stability or its mRNA level; (ii) activation of the p42/p44
MAPK pathway and synthesis of H2O2 are related to HIF-1
induction by LMP1; and (iii) LMP1 induces expression of
VEGF at the transcriptional level, at least in part by activating
HIF-1.
Akt, a proto-oncogene, is a major downstream effector of
growth factor signaling and has a wide array of progrowth and
antiapoptotic effects when activated by growth factors through
PI3K (28). Previous reports suggest that the PI3K/Akt pathway
is central in the regulation of HIF-1 activity (24, 44, 71).
Laughner et al. showed that overexpression of HER2 increases
the rate of HIF-1 protein synthesis that is dependent on the
activity of PI3K, Akt, and the downstream kinase, FKBP-rapa-
mycin-associated protein, at the posttranscriptional level in
mouse 3T3 cells (32). Zundel et al. demonstrated that the
stabilization of the HIF-1 protein by hypoxia was prevented
by overexpression of PTEN, whereas the activation of Akt was
sufficient to promote HIF-1 stabilization under normoxia
(71). In contrast, several reports demonstrated that the activa-
tion of PI3K/Akt by hypoxia is cell type specific and that the
activity of PI3K is not sufficient for the activation of HIF-1, nor
is it essential for its induction by hypoxia (2, 3). The role of the
PI3K signaling pathway in influencing HIF-1 overexpression
remains somewhat confusing and controversial. In our system,
LMP1 did not induce PI3K activity. LMP1-induced HIF-1
expression was not affected by wortmannin, a pharmacological
inhibitor of PI3K. These results suggest that the PI3K pathway
is not involved in LMP1-induced HIF-1 induction.
Recent findings indicate that the p42/p44 MAPK pathway is
involved in HIF-1 activation (38, 45). Richard et al. demon-
strated that HIF-1 is phosphorylated by p42/p44 MAPK in
vitro, not by p38 MAPK or JNK. They also indicated that
activation of the p42/p44 MAPK pathway is sufficient to pro-
mote the transcriptional activity of HIF-1, which was abolished
by the MEK inhibitor PD98059 (45). By use of an in vitro
kinase assay, the C-terminal domain of HIF-1, which contains
the transactivation regions of the protein, was demonstrated to
be phosphorylated directly by p44 MAPK (38). Moreover, one
of the Kaposi’s sarcoma-associated herpesvirus (KSHV) genes
encoded by open reading frame 74, G protein-coupled recep-
tor, upregulates HIF-1 activity through the p42/p44 and p38
MAPK pathways, which results in VEGF expression in nor-
moxia (54). In these reports, there is no increase in the HIF-1
protein level, which indicates a mechanism different from in-
duction of HIF-1 by LMP1, which induces both expression of
HIF-1 protein and HIF-1 activity at least in part in a p42/p44
MAPK pathway-dependent manner. Here we showed that
PD98059 only partially suppressed LMP1-induced HRE re-
porter activity, whereas the drug completely blocked both
LMP1-induced VEGF reporter activity and VEGF secretion.
These results suggest that p42/p44 MAPK signaling plays a
central role in VEGF induction by LMP1 and that LMP1-
induced HIF-1 activity is partially involved in VEGF induction
by LMP1. Previously, we showed that LMP1 induces VEGF
production in part by COX-2 expression, as shown by treat-
ment of cells with NS398, a selective COX-2 inhibitor. How-
ever, residual VEGF production was detected despite this
treatment (40). Possibly, HIF-1 activity and COX-2 contribute
in an additive fashion to induction of VEGF by LMP1.
LMP1 interacts with tumor necrosis factor-associated fac-
tors and activates NF-B signaling (39). Previously, we re-
ported that LMP1 induced COX-2, which resulted in produc-
tion of prostaglandin E2 (PGE2) via NF-B signaling (40).
Recently, involvement of NF-B signaling in HIF-1 induction
FIG. 4. (A) LMP1 does not increase phospho-Akt. To determine whether the PI3K pathway is involved in LMP1-induced HIF-1 expression,
cells were exposed to wortmannin (Wort.), an inhibitor of PI3K. Wortmannin does not suppress LMP1-induced HIF-1 expression. (B) Effect of
NF-B and JNK signaling on LMP1-induced HIF-1 expression. Cotransfection of neither srIB nor JNK1-DN suppresses the induction of
HIF-1 by LMP1, as shown by Western blotting. DMSO, dimethyl sulfoxide.
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has been proposed (15, 25, 26). Microtubule-depolymerizing
agents use an NF-B-dependent pathway to stabilize HIF-1
protein (26). In contrast, Figueroa et al. proposed a novel role
for NF-B in the induction of HIF-1 at the transcriptional
level under hypoxic conditions and reported that the PI3K
pathway was involved in NF-B transactivation (15). Fukuda et
al. showed that in HCT116 cells, PGE2 induced HIF-1 pro-
tein synthesis dependent on p42/p44 MAPK, PI3K, and C-SRC
activity (17). Liu et al. demonstrated that addition of PGE2 to
PC-3ML human prostate cancer cells induced HIF-1 stabili-
FIG. 5. (A) LMP-1 induces binding of HIF-1 to the HRE of the
VEGF promoter. Nuclear extracts of Ad-AH cells transfected with
pcDNA3 or pcLMP1 were incubated with a 32P-labeled probe contain-
ing the HIF-1-binding site from the WT VEGF promoter and analyzed
by electrophoretic mobility shift assay. Excesses of nonlabeled WT
VEGF or MT VEGF were used as competitors. (B) Two promoter
constructs, the HRE (pGL-HRE), and a mutated HRE lacking the
HIF-1 binding site (pGL-HRE mut), are depicted (54). (C and D)
LMP1-induced HRE or VEGF reporter activity was determined by
luciferase assay. Relative HRE or VEGF luciferase activity is HRE
luciferase activity divided by HRE mut activity or 1176/54 lucif-
erase activity divided by 27/54 activity. LMP1 upregulates both
relative HRE and VEGF reporter activities more than twofold, and
this upregulation is suppressed by PD98059 or catalase. Relative lu-
ciferase activity represents the mean and standard deviation of three
separate experiments. (E) VEGF protein level in culture medium
determined by ELISA. LMP1 increases VEGF protein more than
twofold, and this effect is decreased by PD98059 or catalase in a
dose-dependent manner. Values represent the mean and standard
deviation of the VEGF concentration in the medium in three experi-
ments.
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zation, which results from the promotion of HIF-1 translo-
cation from the cytosol to the nucleus. The effects of PGE2 on
HIF-1 were specifically inhibited by PD98059 (34). Jung et al.
demonstrated that interleukin-1 (IL-1)-mediated activation
of NF-B increases COX-2 protein in a lung epithelial cell line
and a colon cell line (25). IL-1-induced NF-B activation is
dependent on the upstream PI3K signaling pathway. PGE2, a
major physiological product of COX-2, is also able to increase
levels of HIF-1 protein, as a result of its increased stability
(25).
It is not clear whether NF-B and/or PGE2 enhance HIF-1
protein levels by promoting its stabilization or its synthesis.
Although NF-B signaling is involved in LMP1-induced
COX-2 expression, the pathway is not involved in HIF-1
induction in our system because cotransfection of srI did
not affect the level of HIF-1. Although involvement of
COX-2 in LMP1-induced HIF-1 expression is not excluded,
NF-B signaling might be only partially involved in LMP1-
induced HIF-1 expression in Ad-AH cells. In our system,
PI3K signaling was not induced by LMP1. It has been reported
that tumor necrosis factor alpha signaling requires phosphor-
ylation events, especially activation of PI3K on HIF-1 stabi-
lization (47). Thus, PI3K signaling activity might be necessary
in NF-B-dependent HIF-1 expression. The influence of
cross talk between NF-B signaling and other signaling path-
way needs to be elucidated.
ROS, such as H2O2, O2
, and OH•, are regulated in cells by
several pathways. Electron transport through the mitochon-
drial respiratory chain is extraordinarily efficient, and normally
most of the O2 is consumed. However, 1 to 2% of the electrons
are leaked to generate O2
 in reactions mediated by coenzyme
Q and ubiquinone and its complex. Thus, mitochondria are
believed to be a major site of ROS production in vivo (21).
Another site of electron transport is the endoplasmic reticu-
lum, where O2
 is generated by the leakage of electrons from
NADPH cytochrome P450 reductase. O2
 is also generated by
hypoxanthine/xanthine oxidase, lipoxygenase, or COX (21).
Superoxide dismutase converts O2
 into H2O2, and then the
H2O2 generated is degraded to H2O by several cellular en-
zymes. ROS have also been implicated in HIF-1 activity (7, 49).
Chandel et al. showed that hypoxia increases mitochondrial
ROS generation at complex III and causes stabilization of
HIF-1 protein and that nonmitochondrial ROS generation is
involved in the response to CoCl2 (8). Angiotensin II increases
HIF-1 translation by ROS-dependent activation of the PI3
kinase pathway that acts on the 5 untranslated region of
HIF-1 mRNA in vascular smooth muscle cells (44). Thiore-
doxin 1, a redox protein that undergoes reversible NADPH-
dependent reduction, increases HIF-1 protein expression
(63).
We showed through flow cytometry by the use of DCFH-DA
that LMP1 increases ROS production. Also, catalase can com-
pletely inhibit the production of ROS by LMP1. Catalase is an
antioxidant that acts as an H2O2 scavenger. These results sug-
gest that ROS generated by LMP1 is mostly H2O2. Interest-
ingly, induction of HIF-1 by LMP1 was dependent on H2O2
generation, since catalase completely inhibited induction of
HIF-1 by LMP1. Catalase could suppress both HRE and
VEGF reporter activities and finally modestly decrease induc-
tion of VEGF by LMP1. These results suggest that H2O2
induced by LMP1 plays an important role in LMP1-induced
VEGF expression. The mechanism of LMP1-induced H2O2
generation needs investigation.
The mechanism of LMP1-induced HIF-1 expression needs
further elucidation. As described above, LMP1-induced
HIF-1 expression is p42/p44 MAPK and ROS dependent and
PI3K independent. The effects of H2O2 on p42/p44 MAPK are
controversial, with some reports showing inhibition and others
demonstrating stimulation. Platelet-derived growth factor-in-
duced H2O2 activates the p42/p44 MAPK pathway, which is
inhibited by incubation with catalase (55). In neonatal rat ven-
tricular myocytes and pulmonary arterial smooth muscle cells,
the p42/p44 MAPK pathway is activated by H2O2 (9, 68). H2O2
activates p42/p44 MAPK in many cell types, although this
activation appears to be cell type specific. Catalase almost
completely blocked angiotensin II-induced H2O2 generation,
which was not accompanied by inhibition of p42/p44 MAPK
activation in vascular smooth muscle cells (59). Furthermore, it
was also reported that H2O2 downregulated p42/p44 MAPK in
human umbilical endothelial cells (33). In our system, LMP1-
induced p42/p44 MAPK activation was not H2O2 dependent,
because catalase, an H2O2-specific scavenger, did not affect
p42/p44 MAPK activity. This result suggests that p42/p44
MAPK and H2O2 stimulate HIF-1 expression through two
converging pathways in LMP1-transfected Ad-AH cells.
These results add to the emerging picture of the ability of
the oncoprotein of a tumor virus to dictate phenotypic changes
in tumor cells in addition to transforming cells (Fig. 6). Fur-
thermore, these and other results suggest the biologic signifi-
cance of our findings. Previously, we have shown that LMP1
induces expression of MMP-9 and in vitro invasiveness, which
are suppressed by aspirin, an IB kinase  inhibitor (41, 66).
Furthermore, we have shown that LMP1 induces several an-
FIG. 6. EBV oncoprotein LMP1 induces cellular invasiveness and
angiogenic factors. LMP1 induces MMP-9, IL-8, FGF-2, and COX-2
through NF-B signaling (41, 60, 65, 66). LMP1 induces HIF-1
through the ROS and p42/p44 MAPK pathways. Thus, LMP1 induces
invasion and angiogenesis factors and finally may promote tumor me-
tastasis. Although induction of HIF-1 by PGE2 has been proposed, it
was not clear in our system (17, 25, 35). Regulation of tumor invasive-
ness by HIF-1 is a topic of interest for future research (31).
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giogenic factors, FGF-2, IL-8, and VEGF (40, 60, 65). NF-B
signaling is involved in the induction of all of these factors by
LMP1. Interestingly, we now find that VEGF is also induced by
LMP1 through synthesis of HIF-1, which uses a pathway
distinct from NF-B signaling. Moreover, we have demon-
strated a significant correlation between expression of LMP1
and microvessel counts in NPC tissue (65). All of these findings
indicate that LMP1 is likely to play a crucial role in tumor
invasiveness and angiogenesis and in resultant metastasis.
LMP1 may produce these effects on tumor cells in later stages
of oncogenesis independently of an etiologic relation between
the virus and the malignancy. LMP1 should be a major target
for gene therapy designed to control invasion and metastasis,
the lethal stage of LMP1-expressing tumors such as NPC.
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